Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes  Lori.

Slides:



Advertisements
Similar presentations
Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma  Timothy S.
Advertisements

Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Retrospective.
Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review 
The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic.
Prognostic Importance of Functional Capacity for Pre-Transplant Risk Assessment Among Patients Undergoing Allogeneic Hematopoietic Cell Transplantation 
Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report.
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis  Sonali.
Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant  Maria Gil-Cupello, BA, Gunjan.
T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL) 
Hideki Nakasone, MD, PhD, David B
Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole  Megan R. Barajas, Kristen.
Allogeneic Hematopoietic Cell Transplantation (HCT) Results in Better Time to Next Therapy (TTNT) Than Chemotherapy (CT) in Chronic Lymphocytic Leukemia.
Vancomycin-Resistant Enterococcus (VRE) Colonization and Blood Stream Infection (BSI): Prevalence, Risk Factors, and Impact on Early Clinical Outcomes.
Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia  Karen K. Ballen, Ann E. Woolfrey, Xiaochun.
Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1  Andrew M. Brunner,
Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes  Lori.
Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia  Hien Duong Liu, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani,
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic.
Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation 
Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow.
Marcelo C. Pasquini, Mei-Jie Zhang, Bruno C
Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR  Gregory.
Outcome of Transplantation for Myelofibrosis
Childhood Obesity and Outcomes after Bone Marrow Transplantation for Patients with Severe Aplastic Anemia  Collin C. Barker, Manza-A. Agovi, Brent Logan,
Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma  Marcel P. Devetten,
David C. Yao, MD, PhD, Paolo Caimi, MD, Hillard M
Donor-Recipient ABO Compatibility Independently Influences Survival after Allogeneic HSCT: Outcomes of 281 Patients from a Single Centre  Duncan Purtill,
Smartphrases: Streamlining Electronic Documentation of Patient Data for CIBMTR Reporting and Clinical Research Compliance  Hannah E. Spencer, MSc, Amy.
Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant  Maria Gil-Cupello, BA, Gunjan.
J. J. Nietfeld, Marcelo C. Pasquini, Brent R
The Role of Post-Remission Chemotherapy before T-Cell Depleted Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia in First Complete Remission 
The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia  Jennifer.
More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes Without Adding Serious Toxicity When Compared to Fludarabine/Melphalan.
Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International.
Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma  Ayman.
Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure  César O. Freytes, Mei-Jie Zhang,
Safety and Efficacy of Amiloride in Reducing the Need for Magnesium Supplementation in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Calcineurin.
Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic.
Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age  Lynda M. Vrooman,
Impact of Extremely Long Driving Distance on Distress and Physical Function in Hematopoietic Cell Transplant Recipients  Rahul Banerjee, Jean C. Yi, Navneet.
Hospital Length of Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative.
Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival  Brian L. McClune, Kwang Woo Ahn, Hai-Lin.
Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International.
Defining the Intensity of Conditioning Regimens: Working Definitions
Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.
Long-Term Prognosis Among 1-Year Survivors of Ex Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation: A Landmark Analysis  Christina.
Biology of Blood and Marrow Transplantation
Members of the Intestinal Microbiota Are Associated with Relapse after Allogeneic Hematopoietic Stem Cell Transplantation  Jonathan U. Peled, MD, PhD,
Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia
Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease.
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse.
Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies  Ensi Voshtina,
Efficacy of Thiotepa-Busulfan-Cyclophosphamide (TBC) Conditioning and Autologous Transplantation As Consolidation for Systemic Non-Hodgkin Lymphoma with.
Moderate/Severe Grade of Chronic Graft Versus Host Disease and Younger Age (Less Than 45 Years Old) Are Risk Factors for Avascular Necrosis in Adult Patients.
Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and.
Jeffrey Schriber, Manza-A. Agovi, Vincent Ho, Karen K
Sustained Suppression of Involved Free Light Chain Predicts Long Term Outcomes in Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation:
Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.
Does Cryopreserved Hematopoietic Stem Cell Product Need an Expiration Date? Recipients Engrafted Despite Infusion of Products over Five Years in Storage.
Parameswaran N. Hari, Navneet S
Athanasios Anagnostopoulos, Parameswaran N. Hari, Waleska S
Survival Improvements in Adolescents and Young Adults after Myeloablative Allogeneic Transplantation for Acute Lymphoblastic Leukemia  William A. Wood,
Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.
Patrick J. Stiff, Manza-A. Agovi, Karen H
Long-Term Outcomes of Patients with Advanced Mantle Cell Lymphoma Treated with Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning 
The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning.
Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation 
The Incidence and Outcomes of Oral Mucositis Among Allogeneic Stem Cell Transplantation Patients: A Systematic Review and Meta-Analysis  Hafsa Myedah.
Results of Allogeneic Double Umbilical Cord Blood Transplantation for Relapsed and Refractory Hodgkin Lymphoma  Philip A. Thompson, MBBS, FRACP, FRCPA,
Presentation transcript:

Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes  Lori Muffly, MD, MS, Marcelo C. Pasquini, MD, MS, Michael Martens, PhD, Ruta Brazauskas, PhD, Xiaochun Zhu, MS, Kehinde Adekola, MD, Mahmoud D. Aljurf, MD, MPH, Andrew S. Artz, MD, MS, Ashish Bajel, MBBS, FRACP, FRCPA, Karen K. Ballen, MD, Minoo Battiwalla, MD, MS, Amer Beitinjaneh, MD, MPH, MS, Jean-Yves Cahn, MD, Matthew Carabasi, MD, Yi-Bin Chen, MD, Saurabh Chhabra, MD, Stefan O. Ciurea, MD, Edward A. Copelan, MD, Anita D'Souza, MD, John Edwards, MD, Cesar O. Freytes, MD, Henry C. Fung, MD, Robert Peter Gale, MD, PhD, Sergio A. Giralt, MD, Shahrukh K. Hashmi, MD, MPH, Peiman Hematti, MD, Gerhard C. Hildebrandt, MD, Vincent T. Ho, MD, Ann A. Jakubowski, PhD, MD, Hillard M. Lazarus, MD, Philip L. McCarthy, MD, Rebecca L. Olin, MD, MSCE, Richard Olsson, MD, PhD, Andrew Rezvani, David A. Rizzieri, MD, Matthew Seftel, Sachiko Seo, MD, PhD, Mohamed L. Sorror, MD, MSc, Jeffrey Szer, MBBS, William A. Wood, MD, MPH  Biology of Blood and Marrow Transplantation  Volume 22, Issue 3, Pages S68-S69 (March 2016) DOI: 10.1016/j.bbmt.2015.11.360 Copyright © 2016 Terms and Conditions

Figure 1 Absolute number of allogeneic transplants in recipients 70 years and older from 2000 to 2013 reported to the CIBMTR by disease category. Biology of Blood and Marrow Transplantation 2016 22, S68-S69DOI: (10.1016/j.bbmt.2015.11.360) Copyright © 2016 Terms and Conditions

Figure 2 OS for allogeneic HCT recipients 70 years and older transplanted between 2000-2007 and 2008-2013. Biology of Blood and Marrow Transplantation 2016 22, S68-S69DOI: (10.1016/j.bbmt.2015.11.360) Copyright © 2016 Terms and Conditions